| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-12-23 | selexipag | pulmonary arterial hypertension (PAH) | 3 | Actelion (Switzerland) | Rare diseases - Cardiovascular diseases |
| 2015-12-22 | AMG 176 | relapsed or refractory multiple myeloma | 1 | Amgen (USA - CA) | Cancer - Oncology |
| 2015-12-22 | MM-121 (seribantumab) | non-small cell lung cancer | 2 | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-12-22 | avelumab (MSB0010718C) | urothelial cancer | 3 | Pfizer (USA - NY) Merck KGaA (Germany) | Cancer - Oncology |
| 2015-12-22 | avelumab (MSB0010718C) | ovarian cancer | 3 | Pfizer (USA - NY) Merck KGaA (Germany) | Cancer - Oncology |
| 2015-12-21 | Samcyprone™ (diphenylcyclopropenone gel) | cutaneous warts caused by human papillomaviruses | 2 | RXi Pharmaceuticals (USA - MA) | Dermatological diseases - Infectious diseases |
| 2015-12-21 | C-Cure®( C3BS-CQR-1) | heart failure | 3 | Celyad (Belgium) | Cardiovascular diseases |
| 2015-12-21 | Adynovate® - BAX 855 | hemophilia A | Baxalta (USA - IL) | Rare diseases - Genetic diseases - Hematological diseases | |
| 2015-12-21 | JNJ-54257099/AL-704 | chronic hepatitits C | 1 | Alios Biopharma, a J&J company (USA - NJ) Janssen Pharmaceutica, a J&J company (USA - NJ) | Infectious diseases |
| 2015-12-21 | AGS-16C3F | metastatic renal cell carcinoma (mRCC) | 2 | Astellas Pharma (Japan) Agensys (USA - CA) | Cancer - Oncology |
| 2015-12-21 | JNJ-64041809/ADU-741 | metastatic castration-resistant prostate cancer (mCRPC) | 1 | Janssen Research & Development, a J&J company (USA - NJ) | Cancer - Oncology |
| 2015-12-21 | CCP-07 | cough | Vernalis (UK) | Respiratory diseases | |
| 2015-12-19 | Keytruda® (pembrolizumab) | patients with non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-containing systemic therapy | 2-3 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2015-12-18 | durvalumab (MEDI4736) | locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations | 2 | AstraZeneca (UK) | Cancer - Oncology |
| 2015-12-18 | AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor, AG-221 (enasidenib) | acute myeloid leukemia (AML) | 1b | Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) | Cancer - Oncology |
| 2015-12-16 | enadenotucirev and pembrolizumab | solid tumors including metastatic colorectal cancer | 1 | PsiOxus Therapeutics (UK) | Cancer - Oncology |
| 2015-12-16 | ALKS 8700 (monomethyl fumarate) | multiple sclerosis | 3 | Alkermes (Ireland) | Autoimmune diseases - Neurodegenerative diseases |
| 2015-12-16 | Bronchitol® (mannitol) | cystic fibrosis | 2 | Pharmaxis (Australia) | Rare diseases - Genetic diseases |
| 2015-12-15 | algenpantucel-L | pancreatic cancer | 3 | NewLink Genetics (USA - IO) | Cancer - Oncology |
| 2015-12-15 | Imlygic® (talimogene laherparepvec) | advanced non CNS tumors | 1 | Amgen (USA - CA) | Cancer - Oncology |
